Zhao Guozhi, Guo Fan, Yan Wenhui, Qu Ying, Yan Chongzheng, Lv Huaiyou, Li Genju, Zhao Jianxiong, Xie Hanmiao, Li Yizhe, Tian Tingting, Zhao Zhongxi
Department of Pharmaceutics, Key Laboratory of Chemical Biology of Ministry of Education, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Cheelloo College of Medicine, Shandong University, Jinan, Shandong Province, 250012, China.
Department of Pharmacy, The Second Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, 247 Beiyuan Street, Jinan, Shandong Province, 250012, China.
Mater Today Bio. 2025 May 20;32:101882. doi: 10.1016/j.mtbio.2025.101882. eCollection 2025 Jun.
Pancreatic cancer is intrinsically characterized by an immunosuppressive microenvironment, in which the malignant extracellular matrix (ECM) creates a barrier that significantly impedes drug delivery, thereby undermining the overall anti-tumor immune responses. In this study, we present a novel thermosensitive hydrogel (SCC15+PLHCu@Gel) that co-deliver two types of nanoparticles loaded with the disulfiram derivative CPD12C15 (SCC15) and tumor-targeting Cu (PLHCu) to overcome the degradation of CPD12C15 induced by Cu within the same nano formulation. SCC15 effectively reduced α-SMA and Collagen I and increased lipid droplets in the cancer-associated fibroblasts (CAFs) by inhibiting the Smad3 pathway, which was consistent with the ECM depletion achieved by using the dosing of SCC15+PLHCu@Gel. In addition, the treatment of SCC15+PLHCu@Gel significantly elevated pro-inflammatory cytokines IFN-γ, TNF-α and IL-12, indicating the remodeling of the suppressive tumor microenvironment. Finally, the immunity modulation effects of SCC15+PLHCu@Gel were evaluated on the enhancement of tumor-infiltrating cytotoxic CD8 T cells, maturation of dendritic cells as well as inhibition of immunosuppressive Tregs and MDSCs. These enhanced antitumor immunity responses might be related to the immunogenic cell death (ICD) effects. Thereby, this study presents a promising therapeutic strategy for targeting the ECM and enhancing the immune responses against pancreatic cancer.
胰腺癌的内在特征是免疫抑制微环境,其中恶性细胞外基质(ECM)形成了一个屏障,显著阻碍药物递送,从而破坏整体抗肿瘤免疫反应。在本研究中,我们提出了一种新型热敏水凝胶(SCC15+PLHCu@Gel),它能共同递送负载有双硫仑衍生物CPD12C15(SCC15)和肿瘤靶向性铜(PLHCu)的两种纳米颗粒,以克服同一纳米制剂中铜诱导的CPD12C15降解。SCC15通过抑制Smad3信号通路,有效降低了癌症相关成纤维细胞(CAF)中的α-SMA和胶原蛋白I,并增加了脂滴,这与使用SCC15+PLHCu@Gel给药实现的ECM消耗一致。此外,SCC15+PLHCu@Gel治疗显著提高了促炎细胞因子IFN-γ、TNF-α和IL-12,表明抑制性肿瘤微环境得到重塑。最后,评估了SCC15+PLHCu@Gel对增强肿瘤浸润性细胞毒性CD8 T细胞、树突状细胞成熟以及抑制免疫抑制性Tregs和MDSCs的免疫调节作用。这些增强的抗肿瘤免疫反应可能与免疫原性细胞死亡(ICD)效应有关。因此,本研究提出了一种有前景的治疗策略,用于靶向ECM并增强针对胰腺癌的免疫反应。
Bioact Mater. 2020-12-26
J Control Release. 2024-12
Nat Rev Gastroenterol Hepatol. 2024-2
Cell. 2023-4-13
Front Cell Infect Microbiol. 2023
Biomaterials. 2022-12